Ping An Healthcare and Technology Company Limited (HKG:1833) Just Reported, And Analysts Assigned A HK$16.50 Price Target
Ping An Healthcare and Technology Company Limited (HKG:1833) Just Reported, And Analysts Assigned A HK$16.50 Price Target
Last week, you might have seen that Ping An Healthcare and Technology Company Limited (HKG:1833) released its interim result to the market. The early response was not positive, with shares down 8.9% to HK$10.00 in the past week. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
上周,您可能已经看到中国平安健康科技股份有限公司(SEHK:1833)发布了其半年报。 早期的反应并不积极,过去一周,股价下跌8.9%至10.00港元。 在此结果公布后,分析师已更新了其盈利模型,很好知道他们是否认为公司前景发生了重大变化,或者是否一切如常。 为此,我们收集了最新的法定预测,以查看分析师对明年的预期。
![1724365165469](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240823/42758480-0-befebb9ad96d5513e2f94d1b5f9498e5.webp/bigjpg)
Following last week's earnings report, Ping An Healthcare and Technology's twelve analysts are forecasting 2024 revenues to be CN¥4.55b, approximately in line with the last 12 months. Earnings are expected to improve, with Ping An Healthcare and Technology forecast to report a statutory profit of CN¥0.093 per share. Before this latest report, the consensus had been expecting revenues of CN¥5.26b and CN¥0.14 per share in losses. So it's pretty clear that although the analysts have made a substantial drop in to their revenue estimates, the business is expected to reach profitability earlier, after the latest results.
在上周的财报发布后,中国平安健康科技的十二位分析师预测2024年营业收入将达到45.5亿元,与过去12个月基本持平。 预计盈利将有所改善,中国平安健康科技预计将报告每股盈利0.093元。在最新财报发布之前,市场预期收入为52.6亿元,每股亏损为0.14元。 因此,显然,尽管分析师对其收入估计有大幅下调,但该企业预计将在最新财报后较早实现盈利。
The analysts have cut their price target 6.2% to HK$16.50per share, suggesting that the declining revenue was a more crucial indicator than the expected improvement in earnings. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Ping An Healthcare and Technology at HK$35.14 per share, while the most bearish prices it at HK$10.00. With such a wide range in price targets, analysts are almost certainly betting on widely divergent outcomes in the underlying business. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.
分析师将其股价目标下调了6.2%,至16.50港元/股,这表明收入下降比预期的盈利改善更为关键。然而,只关注单一的股价目标可能不明智,因为共识目标其实是分析师目标的平均值。因此,一些投资者喜欢查看估计范围,以查看对企业估值是否存在分歧意见。目前,最看好的分析师将中国平安健康科技股票的估值定为35.14港元/股,而最看淡的估值为10.00港元/股。鉴于股价目标的如此大范围,分析师几乎肯定是在对企业的基本业务产生了各不相同的结果。因此,我们不会过于依赖共识股价目标,因为它只是一个平均值,并且分析师对企业的看法明显存在深刻分歧。
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's also worth noting that the years of declining revenue look to have come to an end, with the forecast stauing flat to the end of 2024. Historically, Ping An Healthcare and Technology's top line has shrunk approximately 1.5% annually over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 10% annually. Although Ping An Healthcare and Technology's revenues are expected to improve, it seems that it is still expected to grow slower than the wider industry.
现在来看看更大的画面,了解这些预测的一种方式是看它们与过去的表现和行业增长预期的比较。值得注意的是,下降的营业收入年份似乎已经结束,预测显示到2024年底将保持平稳。根据历史数据,中国平安健康科技的营业收入在过去五年中每年大约下降1.5%。将此与整个行业的分析师预测进行比较,整体上行业收入预计每年增长10%。尽管预计中国平安健康科技的营业收入将有所改善,但似乎仍预计增速略慢于更广泛的行业。
The Bottom Line
最重要的事情是分析师增加了它对下一年每股亏损的估计。令人欣慰的是,营收预测未发生重大变化,业务仍有望比整个行业增长更快。共识价格目标稳定在28.50美元,最新估计不足以对价格目标产生影响。
The most important thing to take away is that there's been a clear step-change in belief around the business' prospects, with the analysts now expecting Ping An Healthcare and Technology to become profitable next year. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. Still, earnings per share are more important to value creation for shareholders. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.
最重要的是,人们明显改变了对业务前景的信念,分析师现在预计中国平安健康科技明年能够盈利。不幸的是,他们还下调了营业收入的预期,我们的数据显示业绩低于更广泛的行业。尽管如此,每股收益对业务的内在价值更为重要。此外,每股收益对股东的价值创造更为重要。此外,分析师还下调了其价格目标,这表明最新的资讯导致对业务内在价值更大的悲观情绪。
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Ping An Healthcare and Technology analysts - going out to 2026, and you can see them free on our platform here.
记住,对于投资者来说,业务的长期轨迹更为重要。我们有来自多位中国平安健康科技分析师的估算,延伸至2026年,你可以在我们的平台上免费查看。
You can also see our analysis of Ping An Healthcare and Technology's Board and CEO remuneration and experience, and whether company insiders have been buying stock.
您还可以看到我们对中国平安健康科技董事会和首席执行官薪酬和经验的分析,以及公司内部人员是否一直在买入股票。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。